Therefore, we propose that the release of a large amount of tumor-derived neoantigens induced by RSL-mediated ferroptosis enhances the repertoire of tumor-specific CD8+ T cells and that anti-PD-1 treatment decreases the extent of exhaustion and promotes the proliferation of these tumor-specific CD8+ T cells to kill tumor cells. The gene discussed is PDCD1; the disease is neoplasm.